Glycemic and Cardiometabolic Effects of Rare Sugars Allulose and Tagatose: A Systematic Review and Meta-Analysis of Controlled Human Intervention Trials
Rare sugars reduce blood sugar spikes compared to regular sugar, though they don't improve cholesterol or weight—useful as a targeted glycemic tool.
This meta-analysis of 20 controlled trials (n=1,033) demonstrates that the rare sugars allulose and tagatose significantly attenuate postprandial glycemic and insulin responses compared to conventional sugars, with moderate certainty evidence. However, neither sugar improved blood lipids, body composition, or uric acid, suggesting they function primarily as glycemic index-lowering sweeteners rather than broad cardiometabolic agents.
What the study was
- Study design
- Systematic review and meta-analysis of 20 controlled human intervention trials
- Population
- Adults in controlled trials evaluating allulose (12 trials) and tagatose (8 trials); 1,033 total participants
- Sample size
- 1033
- Category
- Prevention
- Maturity
- Validated
- Journal
- American Journal of Clinical Nutrition
Why it surfaced
Meta-analysis provides moderate-certainty evidence for rare sugars as glycemic modulators; relevant for dietary recommendations in diabetes prevention; limited cardiometabolic scope.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.